Precursors are prepared and employed in electron beam induced decomposition (EBID). The EBID precursors are complexes of the formula: X-M-Y, where M is Au or Ag; X is F, Cl, Br, I, CN, OR.sup.1, O.sub.2CR.sup.2, or R.sup.3; Y is P(OR).sub.3, NR.sub.3, unsubstituted or substituted pyrrole, unsubstituted or substituted pyridine, unsubstituted or substituted pyrrolidine, or unsubstituted or substituted piperidine; and where R, R.sup.1, R.sup.2, R.sup.3, and substituents of the substituted pyrrole, pyridine, pyrrolidine, or piperidine are independently H, C.sub.1-C.sub.8 alkyl, C.sub.6-C.sub.10 aryl, C.sub.1-C.sub.8 perfluoroalkyl, C.sub.1-C.sub.8 partially fluorinated alkyl, and SiR.sup.5R.sup.6R.sup.7 where R.sup.5, R.sup.6, and R.sup.7 are independently H, C.sub.1-C.sub.8 alkyl, or C.sub.1-C.sub.8 fluorinated alkyl. The decomposition of the EBID precursor results in the formation of one or more gold, silver, or any combination thereof features on a substrate.

The present invention relates to the synthesis of a variety of metal organic frameworks (MOFs) using low temperature and solvents which are considered to be not particularly harmful to the environment. There is also provided novel MOFs which may be made by the desired processes.

Ultrastable silver nanoparticles, methods of making the same, and methods of using the same, are disclosed.

Ultrastable silver nanoparticles, methods of making the same, and methods of using the same, are disclosed.

The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

A compound that is useful for forming a metal by reaction with a reducing agent is described by formula (I): ##STR00001##
wherein M is a metal selected from Groups 2 through 12 of the Periodic Table; and R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are each independently H or C.sub.1-C.sub.8 alkyl.

The present invention relates to compounds of formula (I), which are artemisinin-derivative N-heterocyclic carbene gold (1) hybrid complexes, and to their therapeutic uses.

The present invention relates to compounds of formula (I), which are artemisinin-derivative N-heterocyclic carbene gold (1) hybrid complexes, and to their therapeutic uses.

The present disclosure discloses a method for preparing a metal-organic framework filter comprising the steps of bringing metal sources into contact with organic ligands and forming a metal-organic framework filter on substrates by a hot-pressing method. By the method of the present disclosure, a large amount of metal-organic framework filters with high purity can be obtained quickly and easily, thereby realizing industrialized production and application and the method has such advantages as low cost, simple operation, rapid production, batch product and high purity.

The present disclosure discloses a method for preparing a metal-organic framework filter comprising the steps of bringing metal sources into contact with organic ligands and forming a metal-organic framework filter on substrates by a hot-pressing method. By the method of the present disclosure, a large amount of metal-organic framework filters with high purity can be obtained quickly and easily, thereby realizing industrialized production and application and the method has such advantages as low cost, simple operation, rapid production, batch product and high purity.